MEDICATION MANAGEMENT AND QUALITY USE OF MEDICINES
Dr Manya Angley, Adjunct Professor,
School of Health and Clinical Sciences, Health Professions Education,
University of Western Australia &
Director,
Manya Angley Research and Consulting (MARAC),
Adelaide, South Australia
RESEARCHER PROFILE
Filmed in Adelaide, Australia | July 2026
Adjunct Professor Manya Angley is an Advanced Practice Pharmacist. Manya spent the first 20 years of her career as a teaching and research academic at the University of South Australia. She currently works as a credentialed pharmacist and researcher through her business, Manya Angley Research and Consulting (MARAC).
Her professional activities are focused in general practice, disability and aged care. She continues to undertake research in medicines safety at care transitions and quality use of medicines in the aged care and disability sectors. Manya has just stepped down as SA/NT Branch President of the Pharmaceutical Society of Australia (July 2023-June 2026) was previously vice-president (2022-2023).
Manya was the proud recipient of the Pharmaceutical Society of Australia (SA/NT Branch) Pharmacist of the Year (2021) and the Australian Association of Consultant Pharmacy MIMS Consultant Pharmacist of the Year (2021).
Manya holds, or has held, positions on various multidisciplinary Department of Health, Disability and Ageing (DoHDA) and the ACSQHC technical expert committees. She is regularly invited to present at National pharmacy conferences and to present to other disciplines.
Manya was appointed an Adjunct Professor at the University of Western Australia in 2025.
Source: Supplied
You Might also like
-
Dr Paul Griffin
MATER HEALTH SERVICES, QUEENSLAND, AUSTRALIA
-
Dr James Pang
DR JAMES PANG, RESEARCH FELLOW
TURNER INSTITUTE FOR BRAIN AND MENTAL HEALTH, MONASH UNIVERSITY
VICTORIA, AUSTRALIA -
Therapies for chronic myeloid leukaemia
Professor Tim Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.